药明康德
(603259)
| 流通市值：3874.89亿 | | | 总市值：4748.90亿 |
| 流通股本：24.73亿 | | | 总股本：30.31亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 28,897,478,718.36 | 12,435,776,568.29 | 45,456,165,774.18 | 32,856,716,508.86 |
| 营业收入 | 28,897,478,718.36 | 12,435,776,568.29 | 45,456,165,774.18 | 32,856,716,508.86 |
| 二、营业总成本 | 16,254,491,694.29 | 7,433,446,073.33 | 29,148,154,763.35 | 21,256,267,707.67 |
| 营业成本 | 13,318,999,549.58 | 6,167,822,778.36 | 23,801,434,557.94 | 17,538,098,637.79 |
| 税金及附加 | 235,901,771.31 | 92,179,839.85 | 361,477,739.23 | 273,965,204.62 |
| 销售费用 | 390,792,852.2 | 182,056,633.56 | 806,867,421.28 | 569,374,574.48 |
| 管理费用 | 1,490,526,007.94 | 709,748,017.05 | 2,660,731,035.82 | 1,858,526,669.26 |
| 研发费用 | 605,013,674.54 | 266,956,709.12 | 1,119,452,992.76 | 825,650,523.1 |
| 财务费用 | 213,257,838.72 | 14,682,095.39 | 398,191,016.32 | 190,652,098.42 |
| 其中:利息费用 | 89,688,363.32 | 30,952,924.14 | 268,379,352.78 | 226,711,873.66 |
| 其中:利息收入 | 527,425,948.34 | 274,983,078.16 | 938,021,864.11 | 678,141,337.63 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 684,234,468.06 | 459,260,746.85 | -137,097,911.32 | -34,435,917.65 |
| 加:投资收益 | 227,724,271.36 | 164,837,080.44 | 8,588,017,064.9 | 4,098,539,874.75 |
| 资产处置收益 | -914,869.48 | 2,162,406.4 | -58,067,020.13 | -69,873,339.23 |
| 资产减值损失(新) | -68,368,895.87 | -41,177,323.17 | -541,555,966.37 | -410,113,443.18 |
| 信用减值损失(新) | -93,965,171.38 | -63,930,643.66 | -527,962,030.16 | -346,855,872.7 |
| 其他收益 | 138,631,166.86 | 91,453,793.37 | 298,738,643.85 | 228,351,689.81 |
| 四、营业利润 | 13,530,327,993.62 | 5,614,936,555.19 | 23,930,083,791.6 | 15,066,061,792.99 |
| 加:营业外收入 | 10,728,224.09 | 6,577,970.54 | 31,398,314.78 | 12,551,180.53 |
| 减:营业外支出 | 23,497,152.44 | 14,234,269.52 | 55,330,859.93 | 41,544,623.08 |
| 五、利润总额 | 13,517,559,065.27 | 5,607,280,256.21 | 23,906,151,246.45 | 15,037,068,350.44 |
| 减:所得税费用 | 2,391,225,121.37 | 936,766,274.88 | 4,573,085,354.19 | 2,830,874,889.18 |
| 六、净利润 | 11,126,333,943.9 | 4,670,513,981.33 | 19,333,065,892.26 | 12,206,193,461.26 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 11,083,865,878.49 | 4,652,597,022.26 | 17,977,669,327.23 | 12,339,724,609.74 |
| 终止经营净利润 | 42,468,065.41 | 17,916,959.07 | 1,355,396,565.03 | -133,531,148.48 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 11,080,173,661.42 | 4,651,517,987.76 | 19,150,582,400.69 | 12,075,512,956.92 |
| 少数股东损益 | 46,160,282.48 | 18,995,993.57 | 182,483,491.57 | 130,680,504.34 |
| 扣除非经常损益后的净利润 | 10,572,177,317.83 | 4,275,624,429.82 | 13,240,556,954.42 | 9,522,413,145.23 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 3.8 | 1.59 | 6.7 | 4.25 |
| (二)稀释每股收益 | 3.76 | 1.58 | 6.61 | 4.21 |
| 八、其他综合收益 | -514,298,277.29 | -273,737,529.63 | -449,776,946.3 | -95,953,157.33 |
| 归属于母公司股东的其他综合收益 | -512,206,140.97 | -268,621,140.23 | -447,995,390.63 | -84,806,802.74 |
| 九、综合收益总额 | 10,612,035,666.61 | 4,396,776,451.7 | 18,883,288,945.96 | 12,110,240,303.93 |
| 归属于母公司股东的综合收益总额 | 10,567,967,520.45 | 4,382,896,847.53 | 18,702,587,010.06 | 11,990,706,154.18 |
| 归属于少数股东的综合收益总额 | 44,068,146.16 | 13,879,604.17 | 180,701,935.9 | 119,534,149.75 |
| 公告日期 | 2026-08-04 | 2026-04-28 | 2026-03-24 | 2025-10-27 |
| 审计意见(境内) | | | 标准无保留意见 | |